ABOS — ACUMEN PHARMACEUTICALS INC
Public company
InvestorLens aggregates public filing data to show which tracked investors reported holdings in this stock. Dollar values represent reported position values, not market capitalization, and may be delayed up to 45 days. Not a recommendation.
Sourced from SEC EDGAR public filings
Why are billionaires buying ABOS?
Built from public SEC filings and public economic data. Not a recommendation.
Why? — Evidence & Confidence ▾
Of 2 tracked investors who changed their ABOS position last quarter, 1 bought and 1 sold (50% buy-side). Macro conditions are a headwind for this sector (Macro Tailwind 38/100 in a Expansion regime).
- +1 tracked investor added or increased positions last quarter (Ken Griffin)
- +1 tracked investors reported holding ABOS at their latest filing
- −1 tracked investor reduced or exited last quarter (0 reduced, 1 sold out)
- −Current Expansion regime has historically been a headwind for this sector (Macro Tailwind 38/100)
- −13F data is disclosed up to 45 days after quarter end — positions may have changed since
- · 13F disclosure lag (up to 45 days)
- · Tracked investors are a sample, not the whole market
- · Sector regime fit is a historical average, not a guarantee
Every InvestorLens score shows its evidence — including what argues against it. Model conviction-v1 · generated 11/22/2026.
About ACUMEN PHARMACEUTICALS INC (ABOS)
ACUMEN PHARMACEUTICALS INC (ABOS) appears in the most recent 13F filings of 1 tracked institutional investor. The largest disclosed position is held by Izzy Englander (Millennium Management), valued at $11M. Across recent filings, tracked investors recorded 3 new positions, 6 increased, 9 reduced, and 2 exited. All data sourced from SEC 13F filings.
Based on recent institutional activity in ABOS
How many top investors track ABOS
Only 1 tracked investor report this position.
ABOS Ownership Composition
How ACUMEN PHARMACEUTICALS INC is held across tracked investor types, based on reported 13F positions.
- Multi-Strategy / Quant100.0%
Tracked investors currently reporting ABOS
2 tracked investors have since exited this position — listed separately below.
- Ken GriffinSep 30, 2026Citadel AdvisorsShares110.2KValue$244.6K% Portfolio0.00%
Previously held ABOS
These investors reported ABOS in an earlier quarter but not in their most recent 13F. Figures below are their last reported position, not a current holding.
| Investor | Firm | Last reported shares | Value then | Last held |
|---|---|---|---|---|
| Izzy Englander | Millennium Management | 60.6K | $161.8K | Jun 30, 2026 |
| Steve Cohen | Point72 Asset Management | 67.4K | $159K | Mar 31, 2026 |
Recent activity
- Sold$0(-100.00%)Nov 16, 2026
- Increased$244.6K(115.85%)Nov 16, 2026
- Reduced$4.6M(-6.11%)Nov 14, 2024
- Reduced$2.3M(-26.71%)Feb 14, 2025
- Reduced$1.2M(-15.58%)May 15, 2025
- Increased$2.3M(71.78%)Aug 14, 2025
- Reduced$1.2M(-2.92%)Feb 17, 2026
- Increased$1.6M(12.93%)May 15, 2026
- Reduced$161.8K(-90.81%)Aug 14, 2026
- Reduced$171.9K(-42.00%)Nov 14, 2024
- Reduced$73.3K(-18.28%)May 15, 2025
- Reduced$16.6K(-78.53%)Aug 14, 2025
- Increased$864.8K(3436.42%)Nov 14, 2025
- Reduced$785.1K(-26.42%)Feb 17, 2026
- Increased$136.3K(325.41%)Aug 14, 2026
- New$76.7KFeb 17, 2026
- Increased$159K(85.27%)May 15, 2026
- Sold$0(-100.00%)Aug 14, 2026
- New$289.2KAug 14, 2024
- $10.6MMay 15, 2024
Frequently asked questions
- How many institutional investors hold ABOS?
- 1 tracked institutional investor disclosed a position in ABOS (ACUMEN PHARMACEUTICALS INC) in their most recent 13F filing.
- Who is the largest institutional holder of ABOS?
- Izzy Englander, Millennium Management, holds the largest disclosed position in ABOS, valued at $11M.
- Did institutional ownership of ABOS increase or decrease?
- Across recent 13F filings, tracked investors recorded 3 new positions, 6 increased, 9 reduced, and 2 fully exited ABOS.
- Where does this ABOS ownership data come from?
- SEC Form 13F-HR filings, accessed via EDGAR. 13F filings are disclosed quarterly with a 45-day reporting delay and cover U.S.-listed long equity positions only. This is not investment advice.